

2 March 2026

Biologics Used in Gastroenterology

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Etrasimod**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Mirikizumab**
- **Ozanimod**
- **Risankizumab**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab - Stelara**
- **Ustekinumab Biosimilar**
- **Vedolizumab**
- **Guselkumab**

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Etrasimod**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Mirikizumab**
- **Ozanimod**
- **Risankizumab**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab - Stelara**
- **Ustekinumab Biosimilar**
- **Vedolizumab**

2 March 2026

- **Guselkumab**

Medication	Total Number of Patients	Number of Patients treated for UC
Adalimumab - Humira	11	0
Adalimumab Biosimilar	275	21
Etrasimod	0	0
Filgotinib	20	20
Golimumab	5	5
Infliximab - Remicade	40	12
Infliximab Biosimilar	252	42
Mirikizumab	35	33
Ozanimod	<5	<5
Risankizumab	63	0
Tofacitinib	<5	<5
Upadacitinib	96	39
Ustekinumab - Stelara	7	<5
Ustekinumab Biosimilar	282	61
Vedolizumab	128	94
Guselkumab	<5	0

The infliximab numbers seem really low for UC as we were unable to pull data from therapy plans separately so numbers may not be a full reflection of patients treated. To retrieve this data in full would take in excess of 18 hours. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in locating, retrieving and extracting this information.

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.